Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C21H28O2
CAS Number:
Molecular Weight:
312.45
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
tibolone
manufacturer/tradename
EDQM
drug control
regulated under CDSA - not available from Sigma-Aldrich Canada
mp
165-169 °C
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
O[C@@]1([C@@]2([C@H]([C@H]3[C@H](CC2)C4=C(C[C@H]3C)CC(=O)CC4)CC1)C)C#C
InChI
1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1
InChI key
WZDGZWOAQTVYBX-XOINTXKNSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Tibolone is a synthetic steroid with weak estrogenic, androgenic, and progestogenic activity used in the treatment of menopausal syndrome. Tibolone and its metabolites induce prolactin production in human endometrial stromal cells in vitro. Sulfation plays a major role in the metabolism and regulation of the tissue-specific activity of tibolone and its metabolites.
Application
Tibolone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
I Lambrinoudaki et al.
Climacteric : the journal of the International Menopause Society, 16(2), 258-264 (2012-05-31)
To investigate the effect of tibolone and raloxifene on the serum apoptotic markers soluble Fas (sFas), soluble Fas ligand (sFasL) and cytochrome-c (cyt-c) in postmenopausal women. A total of 89 healthy postmenopausal women, attending the University Menopause Clinic, were randomly
Sarah Sæther et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 132(11), 1330-1334 (2012-06-22)
The Norwegian "Women and cancer" study has shown that when combination hormone replacement products were used for more than five years the relative risk of breast cancer was almost tripled. The population attributable risk was 27 %. In a nested
Ana Raquel Santos de Medeiros et al.
Regulatory peptides, 179(1-3), 55-60 (2012-09-15)
Cardiovascular and immune system abnormalities have been reported in females with estrogen deficiency. To control these disorders in post-menopausal women, hormone replacement therapy (HRT) has been used. Tibolone has been used as a HRT, but the effects of tibolone on